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Improvements in hematopoietic cell transplantation (HCT) have resulted in a wider variety of 
procedures and increased number of transplants for both malignant and non-malignant disorders. 
Technological advances and improved supportive care have increased short-term survival and 
resulted in more long-term transplant survivors. Despite this, treatment-related complications persist 
and overall survival is lower in HCT patients relative to the general population. 
To associate HCT with health complications, Dr. Nandita Khera and colleagues in the Clinical 
Research Division quantify specific health effects in transplant survivors before and after HCT, and 
correlate these results with measures of overall quality of life. Khera et al. focus specifically on the 
late effects of HCT in a contemporary cohort of transplant survivors, including those receiving 
unrelated allogeneic grafts, mobilized blood or umbilical cord transplants, and the more frequent use 
of nonmyeloablative or reduced intensity conditioning regimens to enable HCT for older patients or 
those with preexisting comorbidities. 
Fourteen types of musculoskeletal, endocrine, cardiovascular and organ-specific complications were 
examined in 1,087 Fred Hutchinson Cancer Research Center HCT survivors through annual follow-
up visits or patient questionnaires over approximately three years. Prior to HCT, up to 9.8 percent of 
all patients had health complications. Five years after transplant, the cumulative incidence of one or 
more late effects was 44.8 percent  in autologous recipients who received their own hematopoietic 
cells, and 79  percent in allogeneic recipients who received transplants from others. Overall risk for 
late complications was associated with age greater than 50 years, female sex and having an 
unrelated donor. 
Whereas multiple late effects were rare in autologous recipients, 26 percent of allogeneic recipients 
had three or more late complications. The most frequent events included thyroid disease, 
osteoporosis, pulmonary disease and deep vein thrombosis. In addition, diabetes mellitus, adrenal 
insufficiencies and iron overload were frequent in allogeneic recipients. Survivors with multiple late 
effects also reported worse physical function, more frequent moderate-to-severe limitations of usual 
activities, and lower likelihood of full-time study or employment. 
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These results indicate that current treatment protocols can be further optimized to mitigate long-term 
complications. Options for advancement include modified transplantation techniques, better 
supportive and preventative care, and closer monitoring and education of high-risk patients. 
Furthermore, patients displaying one or more late effects may be particularly suited for screening or 
preventative measures to limit the number of overall late effects resulting from shared risk factors. 
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